

For immediate release

Johnson & Johnson reports Q4 and Full-Year 2025 results

- 2025 Fourth-Quarter reported sales growth of 9.1% to \$24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of \$2.10 and adjusted EPS of \$2.46, both include \$(0.10) due to the acquisition of Halda Therapeutics
- 2025 Full-Year reported sales growth of 6.0% to \$94.2 Billion with operational growth of 5.3%* and adjusted operational growth of 4.2%*; 2025 Full-Year earnings per share (EPS) of \$11.03 and adjusted EPS of \$10.79, both include \$(0.10) due to the acquisition of Halda Therapeutics
- Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma, the acquisition of Halda Therapeutics, and submission of OTTAVA Robotic Surgical System
- Company issues guidance for 2026 with estimated reported sales of \$100.5 Billion or 6.7% at the midpoint, and adjusted EPS⁴ of \$11.53 or 6.9% at the midpoint

New Brunswick, N.J. (January 21, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history" said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. In each of these important areas, our leadership is expanding driven by game-changing science and technology."

Overall financial results

(\$ in Millions, except EPS)	Q4			Full Year		
	2025	2024	% Change	2025	2024	% Change
Reported Sales	\$24,564	\$22,520	9.1%	\$94,193	\$88,821	6.0%
Net Earnings	\$5,116	\$3,431	49.1%	\$26,804	\$14,066	90.6%
EPS (diluted)	\$2.10	\$1.41	48.9%	\$11.03	\$5.79	90.5%
Non-GAAP* (\$ in Millions, except EPS)	Q4			Full Year		
	2025	2024	% Change	2025	2024	% Change
Operational Sales ^{1,2}			7.1%			5.3%
Adjusted Operational Sales ^{1,3}			6.1%			4.2%
Adjusted Net Earnings ^{1,4}	\$6,009	\$4,946	21.5%	\$26,215	\$24,242	8.1%
Adjusted EPS (diluted) ^{1,4}	\$2.46	\$2.04	20.6%	\$10.79	\$9.98	8.1%
Free Cash Flow ^{5,6}				~\$19,700	\$19,842	

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

⁴ Excludes intangible amortization expense and special items

⁵ Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

⁶ Full year 2025 is estimated as of January 21, 2026.

Note: values may have been rounded

Regional sales results

Q4

% Change

(\$ in Millions)	2025	2024	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
U.S.	\$14,195	\$13,204	7.5%	7.5	-	5.7
International	10,369	9,316	11.3	6.6	4.7	6.8
Worldwide	\$24,564	\$22,520	9.1%	7.1	2.0	6.1

Full Year

% Change

(\$ in Millions)	2025	2024	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
U.S.	\$53,752	\$50,302	6.9%	6.9	-	4.9
International	40,441	38,519	5.0	3.4	1.6	3.3
Worldwide	\$94,193	\$88,821	6.0%	5.3	0.7	4.2

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results

Q4

% Change

(\$ in Millions)	2025	2024	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
Innovative Medicine	\$15,763	\$14,332	10.0%	7.9	2.1	6.2
MedTech	8,801	8,188	7.5	5.8	1.7	5.9
Worldwide	\$24,564	\$22,520	9.1%	7.1	2.0	6.1

Full Year

% Change

(\$ in Millions)	2025	2024	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
Innovative Medicine	\$60,401	\$56,964	6.0%	5.3	0.7	4.1
MedTech	33,792	31,857	6.1	5.4	0.7	4.3
Worldwide	\$94,193	\$88,821	6.0%	5.3	0.7	4.2

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Full-year 2025 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 5.3%*, with net acquisitions and divestitures positively impacting growth by 1.2% primarily due to CAPLYTA. Growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,040) basis points impact from STELARA in Immunology.

MedTech

MedTech worldwide operational sales grew 5.4%*, with net acquisitions and divestitures positively impacting growth by 1.1% primarily due to Shockwave. Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular and wound closure products in General Surgery.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

(\$ in Billions, except EPS)	January 2026
Adjusted Operational Sales ^{1,2}	5.4% – 6.4% / 5.9%
Change vs. Prior Year / Mid-point	
Operational Sales ² / Mid-point	\$99.5B – \$100.5B / \$100.0B
Change vs. Prior Year / Mid-point	5.7% – 6.7% / 6.2%
Estimated Reported Sales ³ / Mid-point	\$100.0B – \$101.0B / \$100.5B
Change vs. Prior Year / Mid-point	6.2% – 7.2% / 6.7%
Adjusted Operational EPS (Diluted) ^{2,4} / Mid-point	\$11.28 – \$11.48 / \$11.38
Change vs. Prior Year / Mid-point	4.5% – 6.5% / 5.5%
Adjusted EPS (Diluted) ^{3,4} / Mid-point	\$11.43 – \$11.63 / \$11.53
Change vs. Prior Year / Mid-point	5.9% – 7.9% / 6.9%

¹ Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

² Non-GAAP financial measure; excludes the impact of translational currency

³ Calculated using Euro Average Rate: January 2026 = \$1.17 (Illustrative purposes only)

⁴ Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the [webcast](#).

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations

section of the company's website at [Investor News](#), as well as [Innovative Medicine Newsroom](#), [MedTech News & Events](#), and [www.factsabouttalc.com](#).

Regulatory	Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration ¹	Press Release
	Johnson & Johnson Receives FDA Approval for TRUFILE n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma	Press Release
	U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-Ipui) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE (lazertinib)	Press Release
	U.S. FDA approves AKEEGA as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care	Press Release
	DARZALEX FASPRO is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma	Press Release
	FDA approval of CAPLYTA (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder	Press Release
Data Releases	New clinical data highlights CAPLYTA (lumateperone) as a promising option for achieving remission in adults with major depressive disorder ¹	Press Release
	TECVAYLI monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide ¹	Press Release
	RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer ¹	Press Release
	Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study ¹	Press Release
	Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma	Press Release
	Earlier use of CARVYKTI demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma	Press Release
	Johnson & Johnson's INLEXZO (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC	Press Release
	New long-term data reinforces TREMFYA (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis	Press Release
	Johnson & Johnson announces first head-to-head study comparing IMAAVY with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting	Press Release
	Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis	Press Release
	TREMFYA (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years	Press Release

	Published in <i>The Lancet</i> : Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies	Press Release
	Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis	Press Release
	Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer	Press Release
	TECVAYLI plus DARZALEX FASPRO combination regimen significantly improves progression-free survival and overall survival versus standard of care	Press Release
Other	Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments ¹	Press Release
	Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies	Press Release
	Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business	Press Release

¹ Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the [Johnson & Johnson website](#). A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at [events-and-presentations](#).

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at [www.jnj.com](#).

Non-GAAP financial measures:

* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at [quarterly results](#).

Copies of the financial schedules accompanying this earnings release are available on the company's website at [quarterly results](#). These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of

non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an [Innovative Medicine pipeline](#) of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at [quarterly results](#).

Note to investors concerning forward-looking statements:

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FOURTH QUARTER						TWELVE MONTHS					
				Percent Change						Percent Change	
2025		2024		Total	Operations			2024		Total	Operations
Sales to customers by segment of business											
Innovative Medicine											
U.S.	\$ 9,689	8,977	7.9 %	7.9	-			\$ 36,344	33,970	7.0 %	7.0
International	6,074	5,355	13.4	7.9	5.5			24,057	22,994	4.6	2.9
	15,763	14,332	10.0	7.9	2.1			60,401	56,964	6.0	5.3
MedTech											
U.S.	4,506	4,227	6.6	6.6	-			17,408	16,332	6.6	6.6
International	4,295	3,961	8.5	4.9	3.6			16,384	15,525	5.5	4.1
	8,801	8,188	7.5	5.8	1.7			33,792	31,857	6.1	5.4
U.S.	14,195	13,204	7.5	7.5	-			53,752	50,302	6.9	6.9
International	10,369	9,316	11.3	6.6	4.7			40,441	38,519	5.0	3.4
Worldwide	\$ 24,564	22,520	9.1 %	7.1	2.0			\$ 94,193	88,821	6.0 %	5.3

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FOURTH QUARTER					
	2025	2024	Total	Percent Change	
	2025	2024	Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 14,195	13,204	7.5 %	7.5	-
Europe	5,598	4,921	13.8	5.2	8.6
Western Hemisphere excluding U.S.	1,271	1,135	12.0	11.0	1.0
Asia-Pacific, Africa	3,500	3,260	7.4	7.2	0.2
International	10,369	9,316	11.3	6.6	4.7
Worldwide	\$ 24,564	22,520	9.1 %	7.1	2.0

TWELVE MONTHS

	2025	2024	Total	Percent Change	
	2025	2024	Total	Operations	Currency
	\$ 53,752	50,302	6.9 %	6.9	-
	21,535	20,212	6.5	2.4	4.1
	4,875	4,714	3.4	8.4	(5.0)
	14,031	13,593	3.2	3.1	0.1
	40,441	38,519	5.0	3.4	1.6
	\$ 94,193	88,821	6.0 %	5.3	0.7

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER

	2025		2024		Percent
	Amount	Percent to Sales	Amount	Percent to Sales	Increase (Decrease)
Sales to customers	\$ 24,564	100.0	\$ 22,520	100.0	9.1
Cost of products sold	7,968	32.4	7,128	31.6	11.8
Gross Profit	16,596	67.6	15,392	68.4	7.8
Selling, marketing and administrative expenses	6,753	27.5	6,453	28.6	4.6
Research and development expense	4,252	17.3	5,298	23.5	(19.7)
In-process research and development impairments	81	0.3	17	0.1	
Interest (income) expense, net	(23)	(0.1)	(144)	(0.6)	
Other (income) expense, net	483	2.0	(161)	(0.7)	
Restructuring	84	0.4	42	0.2	
Earnings before provision for taxes on income	4,966	20.2	3,887	17.3	27.8
(Benefit from)/Provision for taxes on income	(150)	(0.6)	456	2.1	(132.9)
Net earnings	\$ 5,116	20.8	\$ 3,431	15.2	49.1
Net earnings per share (Diluted)	\$ 2.10		\$ 1.41		48.9
Average shares outstanding (Diluted)		2,439.0		2,427.1	
Effective tax rate		(3.0) %		11.7 %	
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 7,046	28.7	\$ 5,421	24.1	30.0
Net earnings	\$ 6,009	24.5	\$ 4,946	22.0	21.5
Net earnings per share (Diluted)	\$ 2.46		\$ 2.04		20.6
Effective tax rate		14.7 %		8.8 %	

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS

	2025		2024		Percent
	Amount	Percent to Sales	Amount	Percent to Sales	Increase (Decrease)
Sales to customers	\$ 94,193	100.0	\$ 88,821	100.0	6.0
Cost of products sold	30,256	32.1	27,471	30.9	10.1
Gross Profit	63,937	67.9	61,350	69.1	4.2
Selling, marketing and administrative expenses	23,676	25.1	22,869	25.7	3.5
Research and development expense	14,665	15.6	17,232	19.4	(14.9)
In-process research and development impairments	81	0.1	211	0.2	
Interest (income) expense, net	(85)	(0.1)	(577)	(0.6)	
Other (income) expense, net	(7,209)	(7.6)	4,694	5.3	
Restructuring	228	0.2	234	0.3	
Earnings before provision for taxes on income	32,581	34.6	16,687	18.8	95.2
Provision for taxes on income	5,777	6.1	2,621	3.0	120.4
Net earnings	\$ 26,804	28.5	\$ 14,066	15.8	90.6
Net earnings per share (Diluted)	\$ 11.03		\$ 5.79		90.5
Average shares outstanding (Diluted)	2,429.4		2,429.4		
Effective tax rate	17.7 %		15.7 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 31,681	33.6	\$ 28,979	32.6	9.3
Net earnings	\$ 26,215	27.8	\$ 24,242	27.3	8.1
Net earnings per share (Diluted)	\$ 10.79		\$ 9.98		8.1
Effective tax rate	17.3 %		16.3 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	Fourth Quarter		Twelve Months Ended	
	2025	2024	2025	2024
Net Earnings, after tax- as reported	\$5,116	\$3,431	\$26,804	\$14,066
<i>Pre-tax Adjustments</i>				
Litigation related	854	(16)	(6,040)	5,450
Intangible Asset Amortization expense	1,186	1,171	4,621	4,526
Restructuring related ¹	210	62	512	269
Acquisition, integration and divestiture related	(190)	298	285	1,226
IPR&D Impairments	81	17	81	211
(Gains)/losses on securities	(100)	(68)	(427)	306
Orthopaedics Separation related	48	-	48	-
COVID-19 Vaccine related costs	-	23	-	100
Medical Device Regulation	-	47	-	204
Other	(9)	-	20	-
<i>Tax Adjustments</i>				
Tax impact on special item adjustments ²	(445)	(80)	381	(2,135)
Tax legislation and other tax related	(742)	61	(70)	19
Adjusted Net Earnings, after tax	\$6,009	\$4,946	\$26,215	\$24,242
Average shares outstanding (Diluted)	2,439.0	2,427.1	2,429.4	2,429.4
Adjusted net earnings per share (Diluted)	\$2.46	\$2.04	\$10.79	\$9.98
Operational adjusted net earnings per share (Diluted)	\$2.35		\$10.58	

Notes:

¹ In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of \$102 million in fiscal 2024 included the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of \$162 million in the fiscal fourth quarter of 2025 (\$307 million Q4 2025 YTD) and \$60 million in the fiscal fourth quarter of 2024 (\$167 million Q4 2024 YTD) primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of \$48 million in the fiscal fourth quarter of 2025 (\$205 million Q4 2025 YTD) primarily includes costs related to asset impairments and market and product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

² The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
FOURTH QUARTER 2025 ACTUAL vs. 2024 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
WW As Reported	10.0%	7.5%	9.1%
U.S.	7.9%	6.6%	7.5%
International	13.4%	8.5%	11.3%
WW Currency	2.1	1.7	2.0
U.S.	-	-	-
International	5.5	3.6	4.7
WW Operational	7.9%	5.8%	7.1%
U.S.	7.9%	6.6%	7.5%
International	7.9%	4.9%	6.6%
Caplyta	(1.7)		(1.1)
U.S.	(2.8)		(1.9)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	0.0	0.1	0.1
U.S.	0.0	0.1	0.1
International	0.1	0.2	0.2
WW Adjusted Operational Ex A&D	6.2%	5.9%	6.1%
U.S.	5.1%	6.7%	5.7%
International	8.0%	5.1%	6.8%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
TWELVE MONTHS 2025 ACTUAL vs. 2024 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
WW As Reported	6.0%	6.1%	6.0%
U.S.	7.0%	6.6%	6.9%
International	4.6%	5.5%	5.0%
WW Currency	0.7	0.7	0.7
U.S.	-	-	-
International	1.7	1.4	1.6
WW Operational	5.3%	5.4%	5.3%
U.S.	7.0%	6.6%	6.9%
International	2.9%	4.1%	3.4%
Shockwave		(1.4)	(0.5)
U.S.		(2.1)	(0.7)
International		(0.5)	(0.2)
Caplyta	(1.2)		(0.7)
U.S.	(2.1)		(1.4)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	0.0	0.3	0.1
U.S.	0.0	0.3	0.1
International	0.1	0.2	0.1
WW Adjusted Operational Ex A&D	4.1%	4.3%	4.2%
U.S.	4.9%	4.8%	4.9%
International	3.0%	3.8%	3.3%

Note: Percentages are based on actual, non-rounded figures and may not sum

REPORTED SALES vs. PRIOR PERIOD (\$MM)						
INNOVATIVE MEDICINE SEGMENT ⁽²⁾	FOURTH QUARTER					
			% Change			
	2025	2024	Reported	Operational ⁽¹⁾	Currency	
ONCOLOGY						
US	\$ 3,793	3,019	25.6%	25.6%	-	
Intl	3,069	2,476	23.9%	17.3%	6.6%	
WW	6,861	5,497	24.8%	21.9%	2.9%	
CARVYKTI						
US	420	304	38.2%	38.2%	-	
Intl	135	31	*	*	*	
WW	555	334	65.8%	63.2%	2.6%	
DARZALEX						
US	2,332	1,799	29.6%	29.6%	-	
Intl	1,571	1,285	22.3%	16.2%	6.1%	
WW	3,903	3,084	26.6%	24.1%	2.5%	
ERLEADA						
US	405	342	18.6%	18.6%	-	
Intl	554	442	25.3%	17.5%	7.8%	
WW	959	784	22.4%	18.0%	4.4%	
IMBRUVICA						
US	207	250	(17.4)%	(17.4)%	-	
Intl	478	481	(0.8)%	(7.5)%	6.7%	
WW	684	731	(6.5)%	(10.9)%	4.4%	
RYBREVANT / LAZCLUZE ⁽³⁾						
US	146	101	45.6%	45.6%	-	
Intl	70	21	*	*	*	
WW	216	122	78.0%	76.5%	1.5%	
TALVEY						
US	105	68	53.8%	53.8%	-	
Intl	44	17	*	*	*	
WW	149	85	75.8%	73.1%	2.7%	
TECVAYLI						
US	110	108	2.7%	2.7%	-	
Intl	66	38	72.2%	65.1%	7.1%	
WW	176	146	20.8%	18.9%	1.9%	
ZYTIGA / abiraterone acetate						
US	5	9	(41.4)%	(41.4)%	-	
Intl	115	127	(9.9)%	(11.1)%	1.2%	
WW	119	135	(11.9)%	(13.0)%	1.1%	
OTHER ONCOLOGY						
US	61	39	54.8%	54.8%	-	
Intl	39	36	8.4%	3.0%	5.4%	
WW	100	75	32.9%	30.3%	2.6%	
REPORTED SALES vs. PRIOR PERIOD (\$MM)						
INNOVATIVE MEDICINE SEGMENT ⁽²⁾	TWELVE MONTHS					
			% Change			
	2025	2024	Reported	Operational ⁽¹⁾	Currency	
ONCOLOGY						
US	\$ 13,659	10,854	25.8%	25.8%	-	
Intl	11,721	9,926	18.1%	15.6%	2.5%	
WW	25,380	20,781	22.1%	20.9%	1.2%	
CARVYKTI						
US	1,492	869	71.6%	71.6%	-	
Intl	395	94	*	*	*	
WW	1,887	963	95.9%	94.3%	1.6%	
DARZALEX						
US	8,266	6,588	25.5%	25.5%	-	
Intl	6,085	5,082	19.7%	17.5%	2.2%	
WW	14,351	11,670	23.0%	22.0%	1.0%	
ERLEADA						
US	1,453	1,282	13.4%	13.4%	-	
Intl	2,121	1,717	23.5%	20.1%	3.4%	
WW	3,574	2,999	19.2%	17.2%	2.0%	
IMBRUVICA						
US	892	1,020	(12.5)%	(12.5)%	-	
Intl	1,931	2,018	(4.3)%	(6.7)%	2.4%	
WW	2,823	3,038	(7.1)%	(8.6)%	1.5%	
RYBREVANT / LAZCLUZE ⁽³⁾						
US	534	257	*	*	-	
Intl	200	70	*	*	*	
WW	734	327	*	*	*	
TALVEY						
US	340	241	40.9%	40.9%	-	
Intl	123	46	*	*	*	
WW	463	287	61.3%	60.3%	1.0%	
TECVAYLI						
US	444	418	6.3%	6.3%	-	
Intl	226	131	72.8%	70.4%	2.4%	
WW	670	549	22.1%	21.5%	0.6%	
ZYTIGA / abiraterone acetate						
US	23	34	(33.2)%	(33.2)%	-	
Intl	480	597	(19.7)%	(20.5)%	0.8%	
WW	502	631	(20.4)%	(21.2)%	0.8%	
OTHER ONCOLOGY						
US	214	145	47.5%	47.5%	-	
Intl	162	172	(6.0)%	(7.8)%	1.8%	
WW	376	317	18.5%	17.5%	1.0%	

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)						
FOURTH QUARTER						
% Change						
	2025	2024	Reported	Operational ⁽¹⁾	Currency	
IMMUNOLOGY						
US	\$ 2,495	2,856	(12.6)%	(12.6)%	-	
Intl	1,364	1,383	(1.4)%	(5.5)%	4.1%	
WW	3,860	4,238	(8.9)%	(10.3)%	1.4%	
REMICADE						
US	248	231	7.1%	7.1%	-	
US Exports ⁽⁴⁾	11	9	17.1%	17.1%	-	
Intl	110	117	(5.6)%	(7.3)%	1.7%	
WW	370	359	3.2%	2.6%	0.6%	
SIMPONI / SIMPONI ARIA						
US	287	262	9.6%	9.6%	-	
Intl	345	321	7.4%	3.7%	3.7%	
WW	632	583	8.4%	6.4%	2.0%	
STELARA						
US	766	1,699	(54.9)%	(54.9)%	-	
Intl	462	650	(28.8)%	(32.3)%	3.5%	
WW	1,230	2,349	(47.7)%	(48.6)%	0.9%	
TREMFYA						
US	1,145	654	75.1%	75.1%	-	
Intl	445	295	50.9%	44.0%	6.9%	
WW	1,589	949	67.6%	65.4%	2.2%	
OTHER IMMUNOLOGY						
US	39	0	*	*	-	
Intl	2	0	*	*	*	
WW	40	0	*	*	*	
NEUROSCIENCE						
US	1,439	1,148	25.4%	25.4%	-	
Intl	675	628	7.6%	4.3%	3.3%	
WW	2,115	1,775	19.1%	17.9%	1.2%	
CAPLYTA⁽⁵⁾						
US	249	-	*	*	-	
Intl	-	-	-	-	-	
WW	249	-	*	*	-	
CONCERTA / Methylphenidate						
US	6	33	(79.6)%	(79.6)%	-	
Intl	126	125	(0.3)%	(1.4)%	1.1%	
WW	132	159	(17.1)%	(17.8)%	0.7%	
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA						
US	704	796	(11.5)%	(11.5)%	-	
Intl	281	267	5.2%	1.9%	3.3%	
WW	986	1,063	(7.3)%	(8.2)%	0.9%	
SPRAVATO						
US	438	269	63.0%	63.0%	-	
Intl	64	28	*	*	*	
WW	503	297	69.0%	67.8%	1.2%	
OTHER NEUROSCIENCE						
US	40	49	(18.3)%	(18.3)%	-	
Intl	205	206	(0.7)%	(4.3)%	3.6%	
WW	245	255	(4.1)%	(6.9)%	2.8%	
REPORTED SALES vs. PRIOR PERIOD (\$MM)						
TWELVE MONTHS						
% Change						
	2025	2024	Reported	Operational ⁽¹⁾	Currency	
	\$ 9,872	11,355	(13.1)%	(13.1)%	-	
	5,856	6,473	(9.5)%	(10.2)%	0.7%	
	15,728	17,828	(11.8)%	(12.0)%	0.2%	
	1,171	1,009	16.0%	16.0%	-	
	74	98	(24.8)%	(24.8)%	-	
	523	497	5.3%	6.2%	(0.9)%	
	1,768	1,605	10.2%	10.5%	(0.3)%	
	1,193	1,082	10.3%	10.3%	-	
	1,475	1,108	33.1%	32.8%	0.3%	
	2,668	2,190	21.8%	21.7%	0.1%	
	3,847	6,720	(42.7)%	(42.7)%	-	
	2,230	3,641	(38.7)%	(39.3)%	0.6%	
	6,078	10,361	(41.3)%	(41.5)%	0.2%	
	3,529	2,443	44.5%	44.5%	-	
	1,626	1,227	32.5%	30.4%	2.1%	
	5,155	3,670	40.5%	39.8%	0.7%	
	59	3	*	*	-	
	2	0	*	*	*	
	61	3	*	*	*	
	5,151	4,398	17.1%	17.1%	-	
	2,686	2,718	(1.2)%	(1.8)%	0.6%	
	7,837	7,115	10.1%	9.9%	0.2%	
	700	-	*	*	-	
	700	-	*	*	-	
	82	134	(38.6)%	(38.6)%	-	
	502	507	(1.2)%	(0.7)%	(0.5)%	
	584	641	(9.0)%	(8.6)%	(0.4)%	
	2,725	3,125	(12.8)%	(12.8)%	-	
	1,085	1,097	(1.1)%	(1.8)%	0.7%	
	3,810	4,222	(9.8)%	(9.9)%	0.1%	
	1,485	929	59.9%	59.9%	-	
	210	148	41.9%	39.1%	2.8%	
	1,696	1,077	57.4%	57.0%	0.4%	
	159	210	(24.5)%	(24.5)%	-	
	889	965	(7.9)%	(8.7)%	0.8%	
	1,048	1,175	(10.9)%	(11.5)%	0.6%	

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)							REPORTED SALES vs. PRIOR PERIOD (\$MM)						
FOURTH QUARTER							TWELVE MONTHS						
				% Change							% Change		
		2025	2024	Reported	Operational ⁽¹⁾	Currency			2025	2024	Reported	Operational ⁽¹⁾	Currency
PULMONARY HYPERTENSION													
US		\$ 865	819	5.7%	5.7%	-			\$ 3,223	3,143	2.6%	2.6%	-
Intl		319	274	16.4%	12.2%	4.2%			1,214	1,140	6.5%	4.9%	1.6%
WW		1,184	1,092	8.4%	7.4%	1.0%			4,437	4,282	3.6%	3.2%	0.4%
OPSUMIT / OPSYNVI													
US		458	408	11.9%	11.9%	-			1,633	1,557	4.8%	4.8%	-
Intl		185	162	14.8%	10.9%	3.9%			692	668	3.7%	2.1%	1.6%
WW		643	570	12.7%	11.6%	1.1%			2,325	2,225	4.5%	4.0%	0.5%
UPTRAVI													
US		397	391	1.6%	1.6%	-			1,536	1,511	1.7%	1.7%	-
Intl		94	75	26.9%	20.8%	6.1%			366	307	19.4%	17.4%	2.0%
WW		491	465	5.7%	4.7%	1.0%			1,902	1,817	4.7%	4.3%	0.4%
OTHER PULMONARY HYPERTENSION													
US		10	19	(43.7)%	(43.7)%	-			54	75	(27.0)%	(27.0)%	-
Intl		39	38	2.6%	1.2%	1.4%			155	165	(6.2)%	(6.8)%	0.6%
WW		49	57	(12.5)%	(13.5)%	1.0%			209	240	(12.7)%	(13.0)%	0.3%
INFECTIOUS DISEASES													
US		303	331	(8.5)%	(8.5)%	-			1,264	1,354	(6.6)%	(6.6)%	-
Intl		505	443	13.9%	5.6%	8.3%			1,977	2,042	(3.2)%	(6.5)%	3.3%
WW		807	774	4.3%	(0.4)%	4.7%			3,241	3,396	(4.6)%	(6.5)%	1.9%
EDURANT / rilpivirine													
US		5	7	(39.1)%	(39.1)%	-			26	31	(18.4)%	(18.4)%	-
Intl		379	315	20.6%	11.1%	9.5%			1,461	1,241	17.7%	13.0%	4.7%
WW		383	322	19.2%	9.9%	9.3%			1,486	1,272	16.9%	12.2%	4.7%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA													
US		294	321	(8.4)%	(8.4)%	-			1,226	1,311	(6.5)%	(6.5)%	-
Intl		89	86	3.6%	(2.9)%	6.5%			353	401	(11.9)%	(13.7)%	1.8%
WW		383	407	(5.8)%	(7.2)%	1.4%			1,579	1,712	(7.7)%	(8.1)%	0.4%
OTHER INFECTIOUS DISEASES													
US		4	1	92.9%	92.9%	-			12	11	6.6%	6.6%	-
Intl		37	43	(14.5)%	(18.0)%	3.5%			163	401	(59.3)%	(59.5)%	0.2%
WW		40	45	(9.9)%	(13.2)%	3.3%			175	412	(57.5)%	(57.7)%	0.2%
CARDIOVASCULAR / METABOLISM / OTHER													
US		794	805	(1.4)%	(1.4)%	-			3,175	2,866	10.8%	10.8%	-
Intl		142	153	(6.3)%	(10.7)%	4.4%			603	696	(13.3)%	(13.8)%	0.5%
WW		936	957	(2.2)%	(2.9)%	0.7%			3,778	3,562	6.1%	6.0%	0.1%
XARELTO													
US		687	676	1.7%	1.7%	-			2,633	2,373	11.0%	11.0%	-
Intl		-	-	-	-	-			2,633	2,373	11.0%	11.0%	-
WW		687	676	1.7%	1.7%	-							
OTHER													
US		107	130	(17.4)%	(17.4)%	-			542	494	9.8%	9.8%	-
Intl		142	153	(6.3)%	(10.7)%	4.4%			603	696	(13.3)%	(13.8)%	0.5%
WW		249	281	(11.4)%	(13.8)%	2.4%			1,145	1,189	(3.7)%	(4.0)%	0.3%
TOTAL INNOVATIVE MEDICINE													
US		9,689	8,977	7.9%	7.9%	-			36,344	33,970	7.0%	7.0%	-
Intl		6,074	5,355	13.4%	7.9%	5.5%			24,057	22,994	4.6%	2.9%	1.7%
WW		\$ 15,763	\$ 14,332	10.0%	7.9%	2.1%			\$ 60,401	\$ 56,964	6.0%	5.3%	0.7%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)						REPORTED SALES vs. PRIOR PERIOD (\$MM)					
MEDTECH SEGMENT ⁽²⁾	FOURTH QUARTER					% Change	TWELVE MONTHS				
	2025	2024	Reported	Operational ⁽¹⁾	Currency		2025	2024	Reported	Operational ⁽¹⁾	Currency
CARDIOVASCULAR											
US	\$ 1,374	1,221	12.5%	12.5%	-		\$ 5,305	4,513	17.5%	17.5%	-
Intl	925	841	10.1%	6.8%	3.3%		3,623	3,194	13.4%	11.9%	1.5%
WW	2,299	2,062	11.5%	10.1%	1.4%		8,928	7,707	15.8%	15.2%	0.6%
ELECTROPHYSIOLOGY											
US	746	681	9.5%	9.5%	-		2,891	2,738	5.6%	5.6%	-
Intl	679	640	6.2%	3.2%	3.0%		2,743	2,529	8.5%	7.3%	1.2%
WW	1,425	1,321	7.9%	6.5%	1.4%		5,634	5,267	7.0%	6.4%	0.6%
ABIOMED											
US	358	308	16.5%	16.5%	-		1,393	1,213	14.9%	14.9%	-
Intl	102	77	33.1%	25.4%	7.7%		358	284	26.4%	22.0%	4.4%
WW	460	384	19.8%	18.3%	1.5%		1,751	1,496	17.1%	16.2%	0.9%
SHOCKWAVE											
US	238	202	18.0%	18.0%	-		897	442	*	*	-
Intl	80	56	42.3%	40.7%	1.6%		249	122	*	*	*
WW	318	258	23.3%	22.9%	0.4%		1,146	564	*	*	*
OTHER CARDIOVASCULAR											
US	31	31	(0.1)%	(0.1)%	-		124	120	3.1%	3.1%	-
Intl	64	68	(6.7)%	(8.8)%	2.1%		273	260	4.9%	4.1%	0.8%
WW	95	99	(4.6)%	(6.1)%	1.5%		397	380	4.3%	3.8%	0.5%
ORTHOPAEDICS											
US	1,520	1,460	4.2%	4.2%	-		5,720	5,689	0.5%	0.5%	-
Intl	918	856	7.3%	2.3%	5.0%		3,538	3,470	2.0%	(0.2)%	2.2%
WW	2,438	2,315	5.3%	3.5%	1.8%		9,258	9,158	1.1%	0.3%	0.8%
HIPS											
US	284	272	4.3%	4.3%	-		1,080	1,057	2.1%	2.1%	-
Intl	154	146	5.5%	0.4%	5.1%		594	581	2.2%	0.1%	2.1%
WW	439	418	4.7%	2.9%	1.8%		1,674	1,638	2.1%	1.4%	0.7%
KNEES											
US	251	238	5.1%	5.1%	-		924	922	0.2%	0.2%	-
Intl	181	160	13.7%	9.2%	4.5%		663	623	6.5%	4.6%	1.9%
WW	432	398	8.6%	6.8%	1.8%		1,587	1,545	2.7%	2.0%	0.7%
TRAUMA											
US	543	514	5.6%	5.6%	-		2,058	2,013	2.2%	2.2%	-
Intl	270	250	7.9%	2.7%	5.2%		1,088	1,036	5.0%	2.7%	2.3%
WW	813	764	6.4%	4.7%	1.7%		3,146	3,049	3.2%	2.4%	0.8%
SPINE, SPORTS & OTHER											
US	442	434	1.9%	1.9%	-		1,658	1,696	(2.2)%	(2.2)%	-
Intl	312	300	4.2%	(0.7)%	4.9%		1,193	1,230	(3.0)%	(5.3)%	2.3%
WW	756	735	2.8%	0.8%	2.0%		2,852	2,926	(2.5)%	(3.5)%	1.0%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)						
FOURTH QUARTER						
			% Change			
	2025	2024	Reported	Operational ⁽¹⁾	Currency	
SURGERY						
US	\$ 1,081	1,038	4.2%	4.2%	-	
Intl	1,563	1,469	6.4%	3.4%	3.0%	
WW	2,644	2,507	5.5%	3.7%	1.8%	
ADVANCED						
US	489	478	2.5%	2.5%	-	
Intl	687	673	1.9%	(0.8)%	2.7%	
WW	1,175	1,151	2.2%	0.6%	1.6%	
GENERAL						
US	592	560	5.6%	5.6%	-	
Intl	876	795	10.2%	6.9%	3.3%	
WW	1,468	1,357	8.3%	6.3%	2.0%	
VISION						
US	531	509	4.3%	4.3%	-	
Intl	889	794	11.9%	8.5%	3.4%	
WW	1,420	1,303	8.9%	6.8%	2.1%	
CONTACT LENSES / OTHER						
US	417	396	5.3%	5.3%	-	
Intl	592	541	9.3%	5.3%	4.0%	
WW	1,008	937	7.6%	5.3%	2.3%	
SURGICAL						
US	113	113	0.6%	0.6%	-	
Intl	297	252	17.7%	15.3%	2.4%	
WW	411	365	12.4%	10.8%	1.6%	
TOTAL MEDTECH						
US	4,506	4,227	6.6%	6.6%	-	
Intl	4,295	3,961	8.5%	4.9%	3.6%	
WW	\$ 8,801	8,188	7.5%	5.8%	1.7%	
REPORTED SALES vs. PRIOR PERIOD (\$MM)						
TWELVE MONTHS						
			% Change			
	2025	2024	Reported	Operational ⁽¹⁾	Currency	
	\$ 4,157	4,003	3.9%	3.9%	-	
	5,980	5,842	2.4%	1.5%	0.9%	
	10,137	9,845	3.0%	2.5%	0.5%	
	1,900	1,838	3.4%	3.4%	-	
	2,678	2,650	1.0%	0.1%	0.9%	
	4,577	4,488	2.0%	1.5%	0.5%	
	2,258	2,165	4.3%	4.3%	-	
	3,302	3,192	3.4%	2.7%	0.7%	
	5,560	5,358	3.8%	3.3%	0.5%	
	2,225	2,128	4.6%	4.6%	-	
	3,243	3,018	7.4%	5.9%	1.5%	
	5,468	5,146	6.3%	5.3%	1.0%	
	1,754	1,684	4.1%	4.1%	-	
	2,157	2,049	5.3%	3.2%	2.1%	
	3,910	3,733	4.8%	3.6%	1.2%	
	471	444	6.1%	6.1%	-	
	1,086	969	12.1%	11.6%	0.5%	
	1,558	1,413	10.2%	9.9%	0.3%	
	17,408	16,332	6.6%	6.6%	-	
	16,384	15,525	5.5%	4.1%	1.4%	
	\$ 33,792	31,857	6.1%	5.4%	0.7%	

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE

(4) Reported as U.S. sales

(5) Acquired with Intra-Cellular Therapies on April 2, 2025

Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation \$ in Millions

Quarter to Date

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date

	Fourth Quarter Dec. 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Fourth Quarter Dec. 29, 2024 Non-GAAP
<i>Innovative Medicine</i>											
Cost of products sold	\$ 3,514										2,829
Selling, marketing and admin expenses	3,312										3,312
Research and development expense	3,698										3,692
Other segment items	(201)										(158)
Adjusted Income Before Tax by Segment	4,009	685	(41)	41	(17)	(2)	(12)	50	(6)	23	4,657
<i>MedTech</i>											
Cost of products sold	\$ 3,596										2,928
Selling, marketing and admin expenses	2,836										2,832
Research and development expense	1,600										1,575
Other segment items	84										(33)
Adjusted Income Before Tax by Segment	72	486	(29)	29		(40)	(115)	18	47		886
<i>Expenses not allocated to segments</i>											
Cost of products sold	\$ 18										18
Selling, marketing and admin expenses	305										305
Research and development expense	-										
Other segment items	(129)										(201)
Adjusted Income Before Tax by Segment	(194)										(122)
<i>Johnson & Johnson Consolidated</i>											
Cost of products sold	\$ 7,128										5,775
Selling, marketing and admin expenses	6,453										6,449
Research and development expense	5,298										5,267
Other (Income) / Expense	(161)										(248)
In-process research and development impairments	17										-
Interest (Income)/Expense	(144)										(144)
Restructuring	42										-
Adjusted Income Before Tax	3,887	1,171	(16)	16	17	62	298	(68)	47	23	5,421
Provision for taxes on income	456	171	(158)		4	3	80	(34)	9	5	475
Net Earnings	\$ 3,431	1,000	142		13	59	218	(34)	38	18	4,946

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Year to Date

	Twelve Months Dec. 28, 2025 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Other	Twelve Months Dec. 28, 2025 Non-GAAP
Innovative Medicine											
Cost of products sold	\$ 15,646	(2,706)									12,905
Selling, marketing and admin expenses	11,375										11,375
Research and development expense	11,827										11,827
Other segment items	(713)		90	(11)		(327)	265			(10)	(706)
Adjusted Income Before Tax by Segment	22,266	2,706	(90)	11		362	(265)			10	25,000
MedTech											
Cost of products sold	\$ 14,549	(1,915)									12,491
Selling, marketing and admin expenses	11,354										11,354
Research and development expense	2,838						37				2,875
Other segment items	938		(896)	(70)	(421)	135	162	(48)		(10)	(210)
Adjusted Income Before Tax by Segment	4,113	1,915	896	70	512	(120)	(162)	48		10	7,282
Expenses not allocated to segments											
Cost of products sold	\$ 61										61
Selling, marketing and admin expenses	947										947
Research and development expense	-										-
Other segment items	(7,210)		6,846			(43)					(407)
Adjusted Income Before Tax by Segment	6,202	-	(6,846)	-		43					(601)
Johnson & Johnson Consolidated											
Cost of products sold	\$ 30,256	(4,621)									25,457
Selling, marketing and admin expenses	23,676										23,676
Research and development expense	14,665										14,702
Other (Income) / Expense	(7,209)										(1,238)
In-process research and development impairments	81										-
Interest (Income)/Expense	(85)										(85)
Restructuring	228					(228)					-
Adjusted Income Before Tax	32,581	4,621	(6,040)	81	512	285	(427)	48		20	31,681
Provision for taxes on income	5,777	829	(1,509)	18	93	267	(96)	11	70	6	5,466
Net Earnings	\$ 26,804	3,792	(4,531)	63	419	18	(331)	37	(70)	14	26,215

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Year to Date

	Twelve Months Dec. 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Twelve Months Dec. 29, 2024 Non-GAAP
Innovative Medicine											
Cost of products sold	\$ 14,036								(8)		11,256
Selling, marketing and admin expenses	10,906	(2,772)									10,906
Research and development expense	13,529										13,504
Other segment items	(426)										(1154)
Adjusted Income Before Tax by Segment	18,919	2,772	358	211	102	(66)	76	(76)	100	-	22,452
MedTech											
Cost of products sold	\$ 13,345										11,122
Selling, marketing and admin expenses	10,812	(1,745)									10,796
Research and development expense	3,703										3,530
Other segment items	257	(9)	14			(132)	(69)	(587)	(30)		(487)
Adjusted Income Before Tax by Segment	3,740	1,754	(14)	-	167	1,015	30	204	-	-	6,896
Expenses not allocated to segments											
Cost of products sold	\$ 90										90
Selling, marketing and admin expenses	1,151										1,151
Research and development expense	-										-
Other segment items	4,731			(5,106)			(145)	(352)			(872)
Adjusted Income Before Tax by Segment	(5,972)	-	5,106	-	-	-	145	352	-	-	(369)
Johnson & Johnson Consolidated											
Cost of products sold	\$ 27,471										22,468
Selling, marketing and admin expenses	22,869	(4,517)									22,853
Research and development expense	17,232										17,034
Other (Income) / Expense	4,694	(9)		(5,450)			(69)	(798)	(306)	(25)	(1,936)
In-process research and development impairments	211				(211)					(67)	
Interest (Income)/Expense	(577)										(577)
Restructuring	234					(234)					-
Adjusted Income Before Tax	16,687	4,526	5,450	211	269	1,226	306	204	100	-	28,979
Provision for taxes on income	2,621	644	1,066	47	45	302	(29)	38	22	(19)	4,737
Net Earnings	\$ 14,066	3,882	4,384	164	224	924	335	166	78	19	24,242